FTSE MIB
32.665,21 -944,64 (-2,81%) Dow Jones
38.589,16 -57,94 (-0,15%) Nasdaq
17.688,88 +21,32 (+0,12%) Nikkei 225
38.814,56 +94,09 (+0,24%) Petrolio
78,49 -0,13 (-0,17%) Bitcoin EUR
61.745,97 +184,93 (+0,30%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
Dopo ore:
| Chiusura precedente | 1,6500 |
| Aperto | 1,7000 |
| Denaro | 1,6200 x 100 |
| Domanda | 1,7400 x 100 |
| Min-Max giorno | 1,6509 - 1,7100 |
| Intervallo di 52 settimane | 1,3000 - 13,2000 |
| Volume | |
| Media Volume | 859.384 |
| Capitalizzazione | 2,473M |
| Beta (mensile su 5 anni) | 0,59 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -22,0200 |
| Prossima data utili | 07 ago 2024 - 12 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 11,00 |
GlobeNewswireCyclacel Pharmaceuticals Reports Second Quarter Financial Results and Provides Business Update
- Key Catalysts ahead with Multiple Value Generating Readouts-- Expects to Release Phase 1/2 Data with Oral Fadraciclib -- Signals of Single-agent Efficacy with Oral Plogosertib -- Management to Host Conference Call at 4:30 pm EDT Today- BERKELEY HEIGHTS, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical leader in cell cycle checkpoint control developing innovative medicines based on cancer cell
- GlobeNewswire
Cyclacel Pharmaceuticals to Release Second Quarter 2023 Financial Results
BERKELEY HEIGHTS, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, will announce second quarter 2023 financial results on Wednesday August 9, 2023. The Company will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time on the same day. Conference call information: Call: (800) 225-9448 / international call:
